GS-7340 , 10mMinDMSO , 379270-37-8

CAS NO.：379270-37-8

Empirical Formula: C21H29N6O5P

Molecular Weight: 476.47

MDL number: MFCD23843796

EINECS: 1592732-453-0

PRODUCT Properties

• Melting point: >119°C (dec.)
• Boiling point: 640.4±65.0 °C(Predicted)
• Density: 1.39±0.1 g/cm3(Predicted)
• storage temp.: 2-8°C(protect from light)
• solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• pka: 4.21±0.10(Predicted)
• form: Solid
• color: White to Off-White
• Stability: Hygroscopic
• InChIKey: LDEKQSIMHVQZJK-QTJFZWIYNA-N
• SMILES: C(OC(C)C)(=O)[C@H](C)NP(CO[C@H](C)CN1C2=C(N=C1)C(N)=NC=N2)(OC1=CC=CC=C1)=O |&1:6,12,r|

Description and Uses

Tenofovir alafenamide fumarate is an oral phosphonoamidate prodrug of the reverse transcriptase inhibitor tenofovir. It was approved by the USFDA for the treatment of chronic hepatitis B virus infection with compensated liver disease. Tenofovir alafenamide fumarate was discovered and developed by Gilead as a potentially safer form of the previously approved tenofovir disoproxil fumarate (Viread).

Tenofovir Alafenamide, also known as Tenofovir Impurity 51, is a prodrug of Tenofovir (T018500), which is a reverse transcriptase inhibitor used to treat HIV and Hepatitis B.

Safety

• Symbol(GHS): GHS05,GHS07
• Signal word: Danger
• Hazard statements: H315-H318-H335
• Precautionary statements: P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P310-P321-P362+P364-P332+P313-P403+P233-P405-P501